Polycyclic carbamoylpyridone derivatives, their preparation method and pharmaceutical compositions
Patent Information
- Application Number
- JP2024528461
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-03
- Filing Date
- 2022-11-08
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2042-11-08
AI Technical Summary
【0012】 本発明は以下の有益な効果を有する。 1.本発明の多環式カルバモイルピリドン誘導体は選択的にエイズウイルスのインテグラーゼの活性を抑制することができ、そしてエイズ感染の予防および治療に幅広く使用することが可能である。 2.優れた浸透性およびPK性質を有し、薬物の調製に有利で、また投与の回数を減少させ、患者の投与に対するコンプライアンスを増加させることができる。 3.低い細胞毒性を有し、投与の安全性を向上させ、不良反応が発生するリスクを低下させる。
Smart Images

Figure 2024544557000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the technical field of drugs for treating AIDS infection, in particular to polycyclic carbamoylpyridone derivatives and their preparation methods and pharmaceutical compositions. [Background technology]
[0002] AIDS, collectively known as "Acquired Immune Deficiency Syndrome" (AIDS), is a malignant infectious disease with a high mortality rate caused by infection with the human immunodeficiency virus (HIV). The HIV virus specifically attacks and destroys the body's immune cells, leading to the impairment of the human immune system, which in turn causes a gradual loss of related immune functions and makes the body vulnerable to attack by many diseases, leading to the development of various serious opportunistic infections and tumors, and ultimately to AIDS.
[0003] HIV is a reverse-transcription virus, whose genetic information is stored in ribonucleic acid (RNA). HIV selectively recognizes and invades immune cells (CD4+ lymphocytes) that have CD4 molecules on their surface, interacting with the CD4 molecules through proteins on their surface to enter the host cell. Once inside the host cell, the single-stranded RNA of HIV's genetic material is used as a template, and complementary double-stranded DNA is formed under the action of reverse transcriptase, which enters the host cell nucleus, where it is catalyzed by integrase and integrated into the host cell genome, after which it is transcribed, translated, and degraded into new viral proteins under the action of proteases, and finally becomes new mature viral particles that are released outside the cell to invade more host cells, and repeat the process.
[0004] Integrase has become an ideal target for anti-HIV drugs because there is no functional analogue of integrase in human cells and the toxicity of drugs during use is low. Integrase inhibitors mainly suppress HIV integrase, which is necessary for viral replication, thereby preventing the covalent insertion or integration of the HIV genome into the host cell genome at the early stage of infection, thereby exerting their antiviral effect. Integrase inhibitors have a remarkable therapeutic effect, can rapidly reduce the number of viruses, and are generally well tolerated, and have been included in the first-line treatment in relevant domestic and international guidelines. Integrase inhibitors that are currently on the market include the previous first-generation Elvitegravir (EVG) and Raltegravir (RAL), the recently marketed second-generation Dolutegravir (DTG), Biktarvy combination tablets containing Bictegravir (BIC), and long-acting Cabotegravir (CAB).
[0005] The integrase inhibitors that were marketed earlier have a low drug resistance barrier, and one or two mutations can reduce the virus's susceptibility, and they also have high cross-resistance. Drugs that were marketed later, such as dolutegravir, have a high resistance barrier and have been widely used since they were marketed. Although integrase inhibitors have a high drug resistance barrier, the emergence of drug resistance is inevitable, just like protease inhibitors and reverse transcriptase inhibitors.
[0006] With current medical technology, once infected with HIV, patients will have to take drugs for life. Lifelong treatment has become the long-term goal of highly active antiretroviral therapy (HARRT), but there are still many issues to consider, and drug resistance is one of the issues that cannot be ignored and is a factor that affects the success of HARRT.
[0007] Therefore, it is necessary to develop new integrase inhibitors to improve oral bioavailability, reduce clinical toxicity and side effects, and raise the drug resistance barrier, which is of great significance in providing patients with better drug choices and better compliance. In view of this, the present invention has been presented. Summary of the Invention [Problem to be solved by the invention]
[0008] The object of the present invention is to provide a polycyclic carbamoylpyridone derivative and its preparation method and pharmaceutical composition, which can selectively inhibit the activity of integrase of AIDS virus and is useful for the prevention and treatment of AIDS infection. The present invention is thus realized. [Means for solving the problem]
[0009] In a first aspect of the present invention, there is provided a polycyclic carbamoylpyridone derivative, including a compound represented by formula (I)-1 or formula (I)-2, an isomer, a pharma- ceutically acceptable salt, a hydrate or a solvate thereof, and at least one pair of functional groups selected from the following (1)-(3) forms a spiro ring or a spiro hetero ring together with a carbon atom linked to the A ring: (1) R1 and R2, (2) R3 and R4, (3) R5 and R6 (i.e., when the polycyclic carbamoylpyridone derivative is a compound represented by formula (I)-1, the functional group pair consisting of R1 and R2 or the functional group pair consisting of R3 and R4 form a spiro ring or a spiro heterocycle together with the carbon atom connected to the A ring. When the polycyclic carbamoylpyridone derivative is a compound represented by formula (I)-2, the functional group pair consisting of R1 and R2 or the functional group pair consisting of R5 and R6 form a spiro ring or a spiro heterocycle together with the carbon atom connected to the A ring.). [ka] (wherein R1, R2, R3, R4, R5 and R6 are each independently selected from any one of hydrogen, halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, -OR7, a substituted or unsubstituted aryl group, a substituted or unsubstituted monocyclic heteroaryl ring, a substituted or unsubstituted monocyclic heterocycle, and a cyano group. R7 is selected from any one of hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, and a substituted or unsubstituted alkynyl group. m is any natural number between 0 and 5. When m is 0, the A ring is a 5-membered ring.
[0010] In a second aspect, the present invention provides a method for producing the polycyclic carbamoylpyridone derivative according to any one of the above embodiments, comprising synthesizing the polycyclic carbamoylpyridone derivative by referring to the following synthesis route: [ka]
[0011] In a third aspect, the present invention provides a pharmaceutical composition comprising a compound according to any of the previous embodiments, an isomer, a pharma- ceutically acceptable salt, hydrate or solvate thereof, and a pharma- ceutically acceptable carrier.
[0012] The present invention has the following beneficial effects: 1. The polycyclic carbamoylpyridone derivatives of the present invention can selectively inhibit the activity of AIDS virus integrase, and can be widely used in the prevention and treatment of AIDS infection. 2. It has excellent permeability and PK properties, which is advantageous for drug preparation and can reduce the number of administrations and increase the patient's compliance with administration. 3. It has low cytotoxicity, improving the safety of administration and reducing the risk of adverse reactions. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] In the following, the technical solutions in the embodiments of the present invention will be clearly and completely described so as to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer. In the embodiments, the conditions not specified are carried out under normal conditions or the conditions recommended by the manufacturer. The reagents or equipment used are all ordinary products that can be purchased commercially if the manufacturer is not specified.
[0014] An embodiment of the present invention is a polycyclic carbamoylpyridone derivative, including a compound of formula (I)-1 or (I)-2, an isomer, a pharma- ceutically acceptable salt, a hydrate or a solvate thereof, and at least one pair of functional groups selected from the following (1)-(3) forms a spiro ring or a spiro hetero ring together with the carbon atom linked to the A ring: (1) R1 and R2, (2) R3 and R4, (3) R5 and R6. [ka] (Note that R1, R2, R3, R4, R5, and R6 are each independently selected from any one of hydrogen, halogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, -OR7, a substituted or unsubstituted aryl group, a substituted or unsubstituted monocyclic heteroaryl ring, a substituted or unsubstituted monocyclic heterocycle, and a cyano group. R7 is selected from any one of hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, and a substituted or unsubstituted alkynyl group. m is any natural number between 0 and 5.)
[0015] Furthermore, R1, R2, R3, R4, R5 and R6 are each independently selected from any one of hydrogen, halogen, C1-4 alkyl group, C1-C4 haloalkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group, -OR5, C3-C8 cycloalkyl group, C6-C10 aryl group, 5-6 membered monocyclic heteroaryl ring, 4-6 membered saturated monocyclic heterocycle and cyano group, and at least one pair of functional groups selected from the following (1)-(3) forms a 3-8 membered spiro ring or a 3-8 membered spiro heterocycle together with the carbon atom connected to the A ring: (1) R1 and R2, (2) R3 and R4, (3) R5 and R6; R7 is selected from any one of hydrogen, C1-4 alkyl group, C2-C6 alkenyl group, C2-C6 alkynyl group and C1-C4 haloalkyl group, and m is 0, 1, 2 or 3.
[0016] Furthermore, the tertiary carbon atom linked to the fused pyrazine of the A ring in the compounds of formula (I)-1 and formula (I)-2 has chirality, and the configuration of the compounds of formula (I)-1 and formula (I)-2 may be a single configuration or a mixture of multiple configurations. The isomers include at least one of tautomers, cis-trans isomers, racemates, and optical isomers having a mirror image or non-mirror image relationship. Specifically, the tertiary carbon atom linked to the fused pyrazine of the A ring has an S configuration.
[0017] Furthermore, R1 and R2 are selected from C1-4 alkyl groups, C3-C5 cycloalkyl groups, specifically methyl groups and cyclopropyl groups, among which methyl groups are more specifically R configurations; R3 and R4 are selected from hydrogen, C3-C6 cycloalkyl groups and C3-C6 heterocycloalkyl groups, specifically hydrogen, cyclopropyl groups, cyclopentyl groups, cyclohexyl groups and 6-membered oxygen-containing heterocyclic groups; R5 and R6 are selected from hydrogen, C3-C6 cycloalkyl groups and C3-C6 heterocycloalkyl groups, specifically hydrogen, cyclopropyl groups, cyclobutyl groups, cyclopentyl groups, cyclohexyl groups and 6-membered oxygen-containing heterocyclic groups.
[0018] Furthermore, the polycyclic carbamoylpyridone derivative is selected from any one of the compounds represented by the following structural formulas: [ka] Preferably, [ka] It is.
[0019] The terms referred to in the examples of the present invention have the following meanings. "Halogen" means fluorine, chlorine, bromine, or iodine. A "C1-C4 alkyl group" is a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a sec-butyl group, or a t-butyl group.
[0020] A "cycloalkyl group" is a monovalent group derived from a monocyclic or polycyclic saturated or partially saturated aliphatic carbocyclic ring compound, and C3-C8 cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl groups.
[0021] a cyclooctyl group, a cyclooctenyl group, a cyclopropenyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, or a cycloheptenyl group.
[0022] An "alkenyl group" is a monovalent group derived from a hydrocarbon group, where a C2-C6 alkenyl group is an alkenyl group having from 2 to 6 carbon atoms and containing at least one carbon-carbon double bond, including, but not limited to, vinyl, propenyl, butenyl, 2-methyl-2-butene, 2-methyl-2-pentene, and the like.
[0023] An "alkynyl group" is an alkynyl group having 2-6 carbon atoms and containing at least one carbon-carbon triple bond, including, but not limited to, ethynyl, propargyl, 1-butynyl, 2-butynyl, and the like.
[0024] An "aryl group" is an aromatic cyclic hydrocarbon group having one or more aromatic rings and a fused or non-fused carbocyclic ring system, such as, for example, phenyl or naphthyl. An "aryl group" may be substituted or unsubstituted, and if substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylamino, halogen, thiol, hydroxy, nitro, and cyano groups.
[0025] The term "heteroaryl group" refers to a 5- or 6-membered monocyclic heteroaryl group containing 1 to 4 heteroatoms selected from N, S or O, or a bicyclic heteroaryl group fused with a benzene ring, a pyridine ring or a pyrrole ring, which may be partially saturated, such as a pyridyl group, a pyrimiridyl group, or a furyl group.
[0026] "Spirocycles" are polycyclic groups that share one carbon atom between monocyclic rings, which may contain one or more double bonds, but no ring has a completely conjugated pi-electron system. Depending on the number of rings, spirocycles are divided into bicyclic spirocycles or polycyclic spirocycles, preferably bicyclic spirocycles.
[0027] "Spiroheterocycles" are polycyclic hydrocarbons sharing one atom between monocyclic rings, in which one or more ring atoms are heteroatoms selected from NR6 (R6 is hydrogen, oxygen, alkyl or haloalkyl), oxygen or S(O)n (n is 0, 1 or 2), and the remaining ring atoms are carbon. These groups may contain one or more double bonds, but no ring has a completely conjugated pi-electron system. Depending on the number of rings, heterospirocycles are divided into bicyclic heterospirocycles or polycyclic heterospirocycles, preferably bicyclic heterospirocycles.
[0028] A "pharmaceutically acceptable salt" is a relatively non-toxic acid or base addition salt of a compound provided by an embodiment of the present invention. The acid addition salt is a salt of a compound of formula (I)-1 or (I)-2 provided by an embodiment of the present invention formed with a suitable inorganic or organic acid, such as hydrochloride, fumarate, etc.
[0029] The base addition salt is a salt formed by the compound of formula (I)-1 or (I)-2 provided by the embodiment of the present invention with a suitable inorganic or organic base, such as a sodium salt, a methylamine salt, etc.
[0030] In a second aspect, an embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivative, which is a method for synthesizing the polycyclic carbamoylpyridone derivative by referring to the following synthesis route: [ka]
[0031] That is, the process for preparing the compound represented by formula (I)-1 or (I)-2 provided by the embodiment of the present invention is as follows: compound II is used as a starting material, and reacts with compound III-1 or III-2 under the catalytic action of an acid to obtain intermediate IV-1 or IV-2 through intramolecular ring closure, and intermediate IV-1 or IV-2 is then demethylated.
[0032] Among them, the compound represented by general formula (II) can be prepared by the method provided in Organic. Letter, 2015, 17, 564-567, or by other conventional methods in the art.
[0033] When preparing intermediate IV-1 or IV2, the acid catalyst used may be an organic acid catalyst or an inorganic acid catalyst, such as formic acid, acetic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, magnesium sulfate, sodium sulfate, 4A molecular sieve, magnesium trifluoromethanesulfonate, etc., preferably acetic acid.
[0034] Specifically, the conditions for preparing intermediate IV-1 include: the molar ratio of compound II to compound III-1 is 1:1-1:5, preferably 1:1.5-1:3; the molar ratio of compound II to acid catalyst is 1:1-1:10, preferably 1:4-1:8; the temperature is 30-100°C, preferably 60-80°C; the reaction solvent is acetonitrile, toluene, etc., preferably acetonitrile; and the reaction time is 5 minutes-16 hours.
[0035] The conditions for preparing intermediate IV-2 include: the molar ratio of compound II to compound III-2 is 1:1-1:5, preferably 1:1.5-1:3; the molar ratio of compound II to acid catalyst is 1:1-1:10, preferably 1:4-1:8; the temperature is 30-100°C, preferably 60-80°C; the reaction solvent is acetonitrile, toluene, etc., preferably acetonitrile; and the reaction time is 5 minutes-16 hours.
[0036] When preparing the compound represented by the general formula (I)-1 or (I)-2, the demethylation reagent is boron tribromide, sodium bromide, sodium iodide, magnesium bromide, lithium bromide, magnesium chloride, preferably lithium bromide.
[0037] Specifically, the conditions for preparing the compound represented by general formula (I)-1 include the following: the molar ratio of intermediate IV-1 to demethylation reagent is 1:1-1:10, preferably 1:4-1:6; the reaction temperature is 30-100°C, preferably 50-70°C; the reaction solvent is dichloromethane, tetrahydrofuran, etc., preferably tetrahydrofuran; the reaction time is several minutes to several hours, preferably 5 minutes to 16 hours.
[0038] The conditions for preparing the compound represented by general formula (I)-2 include: the molar ratio of intermediate IV-2 to demethylation reagent is 1:1-1:10, preferably 1:4-1:6; the reaction temperature is 30-1:100°C, preferably 50-70°C; the reaction solvent is dichloromethane, tetrahydrofuran, etc., preferably tetrahydrofuran; the reaction time is several minutes to several hours, preferably 5 minutes to 16 hours.
[0039] In a third aspect, the present invention provides a pharmaceutical composition comprising a compound according to any of the preceding embodiments, an isomer, a pharma- ceutically acceptable salt, hydrate or solvate thereof, and a pharma- ceutically acceptable carrier, wherein the pharma- ceutically acceptable carrier is selected from water for injection, a lyophilized powder supplement, or an oral formulation supplement. The characteristics and performance of the present invention will be described in more detail below with reference to examples.
[0040] Example 1 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (4R, 12aS)-N-(2, 4-difluorophenyl)-7-hydroxy-4-methyl-6, 8-dioxo-6,8,12,12a-tetrahydro-2H, 4H-spiro[cyclopropane-1,3-pyrido[1,2:4,5]pyrazino[2, 1-b][1, 3]oxazine]-9'-carboxamide.
[0041] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Preparation of intermediate 1a: [ka]
[0042] Step 1: Thionyl chloride (20.4 g, 172 mmol) was added to 160 mL of methanol, and the temperature was lowered to 0°C. Compound 1a.1 (12 g, 116 mmol) was added dropwise to the reaction solution. After the addition was completed, the reaction was stirred at room temperature for 5 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to remove the solvent and obtain a concentrate. Methanol / dichloromethane (1:1) was added to the concentrate and concentrated several times to remove the remaining thionyl chloride, obtaining an off-white solid 1a.2 (14.8 g).
[0043] 1 H NMR (400 MHz, CDCl3) δ 8.34 (br s, 3H), 3.79 (br s, 1H), 3.69 (s, 3H), 2.95 (d, J = 15.9 Hz, 1H), 2.72 (d, J = 15.8 Hz, 1H), 1.46 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 171.0, 52.4, 45.1, 38.2, 18.7.
[0044] Step 2: Compound 1a.2 (10 g, 65 mmol) and sodium bicarbonate (35.8 g, 426.8 mmol) were added to a mixture of 120 mL tetrahydrofuran and 80 mL DMSO, and finally benzyl bromide (29.2 g, 170.7 mmol) was added and reacted at 90-100 °C for 12 h with stirring. After cooling to room temperature, the mixture was quenched with water and ethyl acetate, and the organic layer was separated. The mixture was washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. The mixture was purified by silica gel column chromatography and eluted with ethyl acetate and petroleum ether (1:19) to give a white solid 1a.3 (19 g, 98%).
[0045] 1 H NMR (400 MHz, CDCl3) δ 7.40-7.28 (m, 8H), 7.27-7.21 (m, 2H), 3.69 (d, J = 13.7 Hz, 2H), 3.63 (s, 3H), 3.47 (d, J = 13.7 Hz, 2H), 3.40-3.28 (m, 1H), 2.68 (dd, J = 14.0, 8.1 Hz, 1H), 2.32 (dd, J = 14.0, 6.9 Hz, 1H), 1.13 (d, J = 6.7 Hz, 3H). 13 C NMR (100 MHz, CDCl3) δ 172.8, 140.1, 128.9, 128.2, 126.9, 53.4, 51.5, 50.9, 39.2, 14.0.
[0046] Step 3: Compound 1a.3 (0.5 g, 1.7 mmol) was added to 4 mL of anhydrous THF, and cooled to -78°C under nitrogen gas protection. 2.6 mL of LDA (2M THF solution, 3.0 equivalents) was added dropwise and reacted for 1-2 hours with stirring. Then, at -78°C, a terminally substituted bromoalkane was added dropwise, and in the case of the compound in Example 1, 1-bromo-2-chloroethane (1.45 g, 10.1 mmol, 6 equivalents) with n=1 was used. After the addition was completed, the mixture was transferred to room temperature and reacted for 24 hours with stirring. The mixture was quenched with ammonium chloride solution, extracted with ethyl acetate, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a mixture. The mixture was purified by silica gel column chromatography eluted with ethyl acetate and petroleum ether (1:19) to obtain oily product 1a.4 (0.9 g), which was used as it was in the next step reaction.
[0047] Step 4: Compound 1a.4 (0.8 g) was placed in 5 mL of dehydrated THF and DMPU (1:1), cooled to -78°C under nitrogen gas atmosphere, and 5.6 mL of LiHMDS (1M THF solution, 2.5 equivalents) was added dropwise. After the addition was completed, the reaction was allowed to proceed for 4-5 h with stirring at room temperature. The mixture was quenched with ammonium chloride solution, extracted with ethyl acetate, washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a mixture. The mixture was purified by aluminum trioxide column chromatography eluting with ethyl acetate:petroleum ether (1:19) to obtain colorless oil 1a.5 (0.43 g, 30% yield for two steps).
[0048] 1 H NMR (400 MHz, CDCl3) δ 7.32-7.16 (m, 10H), 3.85 (d, J = 13.6 Hz, 2H), 3.55 (s, 3H), 3.40 (d, J = 13.6 Hz, 2H), 3.37 (q, J = 6.9 Hz, 1H), 1.30-1.21 (m, 1H), 0.96 (d, J = 6.9 Hz, 3H), 0.89-0.76 (m, 2H), 0.63-0.54 (m, 1H).
[0049] Step 5: Compound 1a.5 (0.42 g) was added to 10 mL of anhydrous ethyl ether, cooled to 0° C. under a nitrogen gas atmosphere, and lithium aluminum hydride (75 mg, 1.96 mmol, 1.5 equivalents) was added and reacted for 2-3 h with stirring. After the reaction was completed, water was slowly added at 0° C. to quench the reaction, extracted with ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and then purified by aluminum trioxide column chromatography using ethyl acetate:petroleum ether (1:9) as eluent to obtain colorless oil 1a.6 (0.25 g, 65%).
[0050] 1 H NMR (400 MHz, CDCl3) δ 7.44-7.20 (m, 10H), 4.01 (d, J = 13.0 Hz, 2H), 3.52 (dd, J = 11.2, 1.7 Hz, 1H), 3.37 (q, J = 6.8 Hz, 1H), 3.30 (d, J = 13.0 Hz, 2H), 3.19 (d, J = 11.2 Hz, 1H), 0.80 (d, J = 6.8 Hz, 3H), 0.82-0.72 (m, 1H), 0.69-0.61 (m, 1H), 0.33-0.23 (m, 1H), 0.13-0.05 (m, 1H); 13 C NMR (100 MHz, CDCl3) δ 139.0, 129.4, 128.7, 127.4, 72.3, 55.5, 54.1, 22.9, 7.0, 6.5, 5.9.
[0051] Step 6: Compound 1a.6 (0.25 g, 0.84 mmol) was added to 5 mL of methanol, and 80 mg of Pd(OH)2 / C (50% water content on 20% carbon) was added. The mixture was stirred at room temperature for 12 h under a hydrogen gas atmosphere (balloon). After the reaction was completed, the mixture was filtered through diatomaceous earth to remove carbon, and the filtrate was concentrated under reduced pressure to give compound 1a (90 mg, 93%) as a colorless oil.
[0052] 1 H NMR (400 MHz, CDCl3) δ 4.18 (dd, J = 11.2, 1.8 Hz, 1H), 3.48 (s, 1H), 2.94 (dd, J = 11.3, 1.3 Hz, 1H), 2.61 (qd, J = 6.6, 1.2 Hz, 1H), 1.23 (d, J = 6.6 Hz, 3H), 0.69-0.60 (m, 1H), 0.51-0.42 (m, 1H), 0.33-0.20 (m, 2H); 13 C NMR (100 MHz, CDCl3) δ 68.4, 54.8, 25.7, 19.9, 11.4, 7.6.
[0053] Preparation of intermediate 1b: [ka]
[0054] Step 1: Compound 1b.1 (50 g, 158.6 mmol) and N,N'-carbonyldiimidazole (30.8 g, 190.3 mmol) were added to 500 mL acetonitrile, and the mixture was stirred under nitrogen gas protection and heated to reflux for 2-3 h. The mixture was cooled to 0-10°C, and a mixture of 2,4-difluorobenzylamine (27.2 g, 190.3 mmol) and 30 mL acetonitrile was slowly added dropwise. After the addition was completed, the mixture was reacted at room temperature for 1 h. After the reaction was completed, the mixture was quenched by adding 200 mL water, and the acetonitrile was removed by rotary evaporation under reduced pressure. The mixture was diluted with 300 mL ethyl acetate, washed with 300 mL of 2M hydrochloric acid, washed twice with saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain a pale yellow solid. The solid was washed with ethyl ether and then dried to obtain an off-white solid 1b.2 (53.4 g, 77%).
[0055] 1H NMR (400 MHz, CDCl3) δ 10.39 (t, J = 5.4 Hz, 1H), 8.42 (s, 1H), 7.41-7.35 (m, 1H), 6.85-6.77 (m, 2H), 4.62 (d, J = 5.6 Hz, 2H), 4.50 (t, J = 4.8 Hz, 1H), 4.04 (d, J = 4.8 Hz, 2H), 3.99 (s, 3H), 3.96 (s, 3H), 3.39 (s, 6H).
[0056] Step 2: Compound 1b.2 (20 g, 45.4 mmol) was added to 100 mL formic acid and stirred at 60 °C for 3 h. After the reaction was completed, the solvent was removed by rotary evaporation, diluted with acetonitrile and concentrated several times, added to 80 mL methyl-t-butyl ether and stirred for 10-12 h to precipitate crystals, filtered, and dried to obtain a white solid 1b (17.2 g).
[0057] 1 H NMR (400 MHz, DMSO-d6)(hydrate) δ 10.31 (t, J = 5.8 Hz, 1H), 8.46 (s, 1H), 7.45-7.39(m, 1H), 6.28-6.72 (m, 1H), 7.10-7.05 (m, 1H), 6.39 (d, J = 5.8 Hz, 2H), 4.96 (t, J = 5.6 Hz, 1H), 4.53 (d, J = 5.7 Hz, 2H), 3.95 (d, J=5.1 Hz, 2H), 3.93(s, 3H), 3.81(s, 3H).
[0058] Compound 1b is the acetal deprotection product ( 1 H NMR showed that it was mainly a hydrate), but no matter what the structural form is, it does not affect the ring-closing reaction, so in the following examples, compound 1b (MW: 412.1) is calculated as a hydrate. Preparation of Compound 1 [ka]
[0059] Step 1: Compound 1b (160 mg, 0.39 mmol), compound 1a (90 mg, 0.78 mmol) and acetic acid (140 mg, 2.34 mmol) were added to 2 mL of acetonitrile and reacted for 5-6 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 1c, which was used as it was in the next step reaction. MS m / z (ESI): 460.2 [M+1] + .
[0060] Step 2: Intermediate 1c was added to anhydrous THF, and LiBr (4.0 equivalents) was added and reacted at 70-80°C with stirring for 5-6 h. After the reaction was completed, the mixture was quenched with 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 1 (off-white solid, 128 mg, 74.0% yield for two steps). MS m / z (ESI): 446.2 [M+1] + .
[0061] 1 H NMR (400 MHz, DMSO-d6) δ 12.51 (br s, 1H), 10.36 (t, J = 5.9 Hz,1H), 8.53 (s, 1H), 7.42-7.36 (m, 1H), 7.27-7.21 (m, 1H), 7.09-7.04 (m, 1H ), 5.53(t, J = 4.6 Hz, 1H), 4.59 (dd, J = 14.1, 3.9 Hz, 1H), 4.55 (d, J = 5.9 Hz, 2H), 4.49 (dd, J = 14.0, 5.0 Hz, 1H), 4.33 (d, J = 11.8 Hz, 1H), 4.09 (q, J = 6.9 Hz, 1H), 3.10 (d, J =11.8 Hz, 1H), 1.37 (d, J = 7.0 Hz, 3H), 0.56-0.52 (m, 3H), 0.44-0.42 (m, 1H).
[0062] Example 2 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (4'R, 12a'S)-N-(2, 4-difluorophenyl)-7'-hydroxy-4'-methyl-6', 8'-dioxo-6',8',12',12a'-tetrahydro-2'H, 4'H-spiro[cyclobutane-1,3'-pyrido[1',2':4,5]pyrazino[2, 1-b][1, 3]pyrazine]-9'-carboxamide.
[0063] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Intermediate 2a [ka] Preparation of intermediate 1a: Refer to the synthesis of intermediate 1a in Example 1, where the bromoalkane chloride in step 3 was converted to 1-bromo-3-chloropropane (n=2), which was then subjected to LDA catalyzed substitution and ring closure with LiHMDS to obtain a cyclobutane spiro intermediate, which was then reduced and deprotected to prepare intermediate 2a (colorless oil, 490 mg).
[0064] 1 H NMR (400 MHz, CDCl3) δ 3.89 (dd, J = 11.1, 1.2 Hz, 1H), 3.67 (dd, J = 11.0, 1.2 Hz, 1H), 3.43 (s, 1H), 3.29 (qd, J = 6.6, 1.2 Hz, 1H), 2.15-2.00 (m, 1H), 1.97-1.75 (m, 3H), 1.71-1.60 (m, 1H), 1.52-1.41 (m, 1H), 1.01 (d, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 67.9, 55.5, 44.4, 27.9, 26.3, 16.8, 14.9.
[0065] Synthesis of compound 2: [ka]
[0066] Step 1: Compound 1b (412 mg, 1 mmol), compound 2a (260 mg, 2 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and reacted for 6-7 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 2c, which was used as it was in the next step reaction. MS m / z(ESI): 474.2[M+1] + .
[0067] Step 2: Intermediate 2c was added to anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was reacted at 70-80° C. for 7-8 h with stirring. After the reaction was completed, the mixture was quenched with 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 2 (off-white solid, 260 mg, 56.6% yield for two steps). MS m / z(ESI): 460.2[M+1] + .
[0068] 1H NMR (400 MHz, CDCl3) δ 12.48(br s, 1H), 10.38 (t, J = 5.84 Hz, 1H), 8.32(s, 1H), 7.39-7.33 (m, 1H), 6.84-6.77 (m, 2H), 5.18 (dd, J = 6.0, 4.1 Hz,1H), 4.88 (q, J = 7.0 Hz, 1H), 4.65 (dd, J = 15.9, 6.1 Hz, 1H), 4.61 (dd, J = 15.9, 6.0 Hz, 1H), 4.28 (dd, J = 13.6, 4.1 Hz, 1H), 4.12 (dd, J = 13.5, 5.9 Hz, 1H), 3.92 (d, J = 12.2 Hz, 1H), 3.87 (d, J = 11.8 Hz, 1H), 2.07-1.55 (m, 6H), 1.23 (d, J = 7.0 Hz, 3H).
[0069] Example 3 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (4'R, 12a'S)-N-(2, 4-difluorophenyl)-7'-hydroxy-4'-methyl-6', 8'-dioxo-6',8',12',12a'-tetrahydro-2'H, 4'H-spiro[cyclopentane-1,3'-pyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazine]-9'-carboxamide.
[0070] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Intermediate 3a [ka] Preparation of intermediate 3a: Refer to the synthesis of intermediate 1a in Example 1, in which the bromoalkane chloride in step 3 is converted to 1-bromo-4-chlorobutane (n=4), which is then converted to a cyclopentane spiro intermediate through LDA catalytic substitution and ring closure with LiHMDS, followed by reduction and deprotection to prepare intermediate 3a (colorless oil, 320 mg).
[0071] 1 H NMR (400 MHz, CDCl3) δ 3.73 (dd, J = 10.9, 1.3 Hz, 1H), 3.45 (s, 1H), 3.34 (dd, J = 10.9, 1.3 Hz, 1H), 3.06 (qd, J = 6.6, 1.3 Hz, 1H), 2.01-1.89 (m, 1H), 1.72-1.50 (m, 4H), 1.40-1.20 (m, 3H), 1.18 (d, J = 6.6 Hz, 3H); 13 C NMR (100 MHz, CDCl3) δ 68.1, 56.6, 49.5, 33.7, 32.1, 25.3, 25.2, 19.0.
[0072] Synthesis of compound 3: [ka]
[0073] Step 1: Compound 1b (412 mg, 1 mmol), compound 3a (311 mg, 2.17 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and reacted for 6-7 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 3c, which was used as it was in the next step reaction. MS m / z(ESI): 488.2[M+1] + .
[0074] Step 2: Intermediate 3c was added to anhydrous THF, and LiBr (5.0 equivalents) was added and reacted at 70-80°C with stirring for 8 h. LiBr (5.0 equivalents) was then added and reacted for 12 h. After the reaction was completed, the mixture was quenched with 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 2 (light yellow solid, 170 mg, 36.0% yield for two steps). MS m / z (ESI): 474.2 [M+1] + .
[0075] 1 H NMR (400 MHz, CDCl3) δ 12.48 (br s, 1H), 10.40 (t, J = 5.8 Hz, 1H), 8.33 (s, 1H), 7.39-7.33 (m, 1H), 6.84-6.77 (m, 2H), 5.24 (dd, J = 6.1, 4.2Hz, 1H), 4.69-4.59 (m, 3H), 4.28 (dd, J = 13.6, 4.2 Hz, 1H), 4.13 (dd, J = 13.5, 6.2 Hz, 1H), 3.82 (d, J = 11.2 Hz, 1H), 3.56 (d, J = 11.6 Hz, 1H), 1.87-1.16 (m, 8H), 1.33 (d, J = 7.04 Hz, 3H).
[0076] Example 4 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (4'R, 12a'S)-N-(2, 4-difluorophenyl)-7'-hydroxy-4'-methyl-6', 8'-dioxo-6',8',12',12a'-tetrahydro-2'H, 4'H-spiro[cyclohexane-1,3'-pyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazine]-9'-carboxamide.
[0077] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Intermediate 4a [ka] Preparation of intermediate 4a (colorless oil, 130 mg) was prepared by referring to the synthesis of intermediate 1a in Example 1, where the bromoalkane chloride in step 3 was substituted with 1-bromo-5-chloropentane (n=5), which was then substituted with LDA catalyst and cyclized with LiHMDS to obtain a cyclohexane spiro intermediate, which was then reduced and deprotected.
[0078] 1 H NMR (400 MHz, CDCl3) δ 3.77 (d, J = 11.1 Hz, 1H), 3.59 (dd, J = 11.2, 1.4 Hz, 1H), 3.03 (qd, J = 6.6, 1.4 Hz, 1H), 1.93-1.80 (m, 1H), 1.63-1.39 (m, 4H), 1.35-1.25 (m, 4H), 1.14 (d, J = 6.6 Hz, 3H), 1.08-0.97 (m, 1H); 13 C NMR (100 MHz, CDCl3) δ 66.5, 55.6, 38.5, 30.9, 30.4, 26.4, 21.7, 21.5, 17.4.
[0079] Synthesis of compound 4: [ka]
[0080] Step 1: Compound 1b (173 mg, 0.42 mmol), compound 4a (130 mg, 0.84 mmol) and acetic acid (185 mg, 2.5 mmol) were added to 2 mL of acetonitrile and reacted for 7-8 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 4c, which was used as it was in the next step reaction. MS m / z (ESI): 502.2 [M+1] + .
[0081] Step 2: Intermediate 4c was added to anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was reacted at 70-80°C for 22 h with stirring. After the reaction was completed, the mixture was quenched by adding 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 4 (light yellow solid, 90 mg, 43.9% yield for two steps). MS m / z (ESI): 488.2 [M+1] + .
[0082] 1 H NMR (400 MHz, CDCl3) δ 12.52 (br s, 1H), 10.41 (t, J = 8.96 Hz, 1H), 8.36 (s, 1H), 7.38-7.35 (m, 1H), 6.84-6.77 (m, 2H), 5.17 (t, J = 4.8 Hz, 1H), 4.87 (q, J = 7.0 Hz, 1H), 4.68-4.58 (m, 2H), 4.32 (dd, J = 13.6, 3.8 Hz, 1H), 4.15 (dd, J = 13.6, 5.4 Hz, 1H), 3.73 (d, J = 12.0 Hz, 1H), 3.67 (d, J = 12.0 Hz, 1H), 1.57-1.08 (m, 10H), 1.31 (d, J = 7.08 Hz, 3H).
[0083] Example 5 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (4'R, 12a'S)-N-(2, 4-difluorophenyl)-7'-hydroxy-4'-methyl-6', 8'-dioxo-2,3,5.6,6',8',12',12a'-octahydro-2'H, 4'H-spiro[pyran-4,3'-pyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazine]-9'-carboxamide.
[0084] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Intermediate 5a [ka] Preparation of intermediate 4a (colorless oil, 0.29 g) was prepared by referring to the synthesis of intermediate 1a in Example 1, where the bromoalkane chloride in step 3 was converted to 1-bromo-2-(2-chloroethoxy)ethane, which was then subjected to LDA catalyzed substitution and ring closure with LiHMDS to obtain a pyran spiro intermediate, which was then reduced and deprotected to prepare intermediate 4a (colorless oil, 0.29 g).
[0085] 1 H NMR (400 MHz, CDCl3) δ 3.80-3.75 (m, 3H), 3.74-3.68 (m, 1H), 3.64 (td, J = 11.8, 2.6 Hz, 1H), 3.43 (td, J = 11.8, 3.0 Hz, 2H), 2.95 13C NMR (100 MHz, CDCl3) δ 64.1, 63.68, 63.65, 57.1, 36.6, 30.5, 17.0.
[0086] Synthesis of compound 5: [ka]
[0087] Step 1: Compound 1b (412 mg, 1 mmol), compound 5a (270 mg, 1.7 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and reacted for 7-8 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 5c, which was used as it was in the next step. MS m / z(ESI): 504.2[M+1] + .
[0088] Step 2: Intermediate 5c was added to anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was stirred at 70-80°C for 21 h. After the reaction was completed, the mixture was quenched with 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 4 (light yellow solid, 72 mg, 14.7% yield for two steps). MS m / z (ESI): 490.2 [M+1] + .
[0089] 1H NMR (400 MHz, CDCl3) δ 12.38 (br s, 1H), 10.37 (t, J = 5.9 Hz, 1H), 8.38 (s, 1H), 7.38-7.32 (m, 1H), 6.84-6.77 (m, 2H), 5.21 (t, J = 5.2 Hz, 1H), 4.91 (q, J = 7.0 Hz, 1H), 4.65 (dd, J = 16.3, 5.1 Hz, 1H), 4.61 (dd, J = 16.6, 5.1 Hz, 1H), 4.17 (dd, J = 13.7, 4.1 Hz, 1H), 3.98 (d, J = 12.1 Hz, 1H), 3.88 (d, J = 12.1 Hz, 1H), 3.80-3.55 (m, 4H), 1.78-1.72 (m, 1H), 1.64-1.59 (m, 1H), 1.54-1.48 (m, 1H), 1.34 (d, J = 7.1 Hz, 3H), 1.32-1.29 (m, 1H).
[0090] Example 6 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (4'R, 12a'S)-N-(2, 4-difluorophenyl)-7'-hydroxy-4'-methyl-6', 8'-dioxo-3',4',6',8',12',12a'-hexahydrospiro[cyclopropane-1,2'-pyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazine]-9'-carboxamide.
[0091] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Preparation of intermediate 6a: [ka]
[0092] Step 1: Compound 1a.3 (500 mg, 1.7 mmol) was placed in anhydrous THF (10 mL) and cooled to -30 °C under nitrogen gas protection. Ti(O i Pr)4 (0.25 equiv.) and EtMgbrs (3M / Et2O, 3.0 equiv.) were added dropwise, and the mixture was allowed to react for 10-12 h while stirring at room temperature. After completion of the reaction, the mixture was quenched with ammonium chloride solution, extracted with ethyl acetate, washed with sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Separation was performed by aluminum trioxide column chromatography and eluted with ethyl acetate:petroleum ether (1:9) to give intermediate 6a.1 (colorless oil, 254 mg, 51%).
[0093] 1 H NMR (400 MHz, CDCl3) δ 7.40-7.19 (m, 10H), 6.78 (s, 1H), 3.99 (d, J = 12.9 Hz, 2H), 3.38-3.24 (m, 1H), 3.28 (d, J = 12.9 Hz, 2H), 2.52 (ddd, J = 14.3, 12.4, 1.9 Hz, 1H), 1.07 (d, J = 6.7 Hz, 3H), 0.77 (dd, J = 14.6, 2.9 Hz, 1H), 0.74-0.65 (m, 1H), 0.39-0.22 (m, 2H), 0.01-(-0.10) (m, 1H); 13 C NMR (100 MHz, CDCl3) δ 138.5, 129.5, 128.5, 127.4, 56.6, 53.6, 53.3, 40.1, 12.7, 12.6, 12.0.
[0094] Step 2: The reaction for removing the Bn protecting group was carried out in accordance with Step 6 for compound 1a to obtain compound 6a (colorless oil, 390 mg, ∼100%). 1H NMR (400 MHz, CDCl3) δ: 3.46 (s, 1H), 3.35-3.19 (m, 1H), 1.80 (ddd, J = 14.4, 9.9, 1.7 Hz, 1H), 1.28-1.22 (m, 1H), 1.17 (d, J = 6.4 Hz, 3H), 0.82-0.73 (m, 1H), 0.73-0.65 (m, 1H), 0.50-0.38 (m, 1H), 0.38-0.29 (m, 1H).
[0095] Preparation of compound 6: [ka]
[0096] Step 1: Compound 1b (268 mg, 0.65 mmol), compound 6a (150 mg, 1.3 mmol) and acetic acid (234 mg, 3.9 mmol) were added to 3 mL of acetonitrile and reacted for 6-8 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 6c, which was used as it was in the next step reaction. MS m / z (ESI): 460.2 [M+1] + .
[0097] Step 2: Intermediate 6c was added to anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was reacted at 70-80°C for 14 h with stirring. After the reaction was completed, the mixture was quenched by adding 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 4 (light yellow solid, 110 mg, 38% yield for two steps). MS m / z (ESI): 446.2 [M+1] + .
[0098] 1H NMR (400 MHz, CDCl3) δ 12.50 (br s, 1H), 10.39 (t, J = 5.8 Hz, 1H), 8.36 (s, 1H), 7.38-7.32 (m, 1H), 6.84-6.76 (m, 2H), 5.21 (t, J = 5.2 Hz, 1H), 5.08-5.01 (m, 1H), 4.63 (dd, J = 16.3, 6.2 Hz, 1H), 4.59 (dd, J = 16.0, 6.1 Hz, 1H), 4.35 (dd, J = 13.4, 3.0 Hz, 1H), 4.15 (dd, J = 12.5, 5.0 Hz, 1H), 2.62 (dd, J = 13.1, 5.2 Hz, 1H), 1.49 (d, J = 7.1 Hz, 3H), 1.13 (dd, J = 13.9, 1.1 Hz, 1H), 1.05-0.98 (m, 1H), 0.88-0.82 (m, 1H), 0.70-0.64 (m, 1H), 0.56-0.50 (m, 1H).
[0099] Example 7 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (4'R, 12a'S)-N-(2, 4-difluorophenyl)-7'-hydroxy-4'-methyl-6', 8'-dioxo-3',4',6',8',12',12a'-hexahydrospiro[cyclopentane-1,2'-pyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazine]-9'-carboxamide.
[0100] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Preparation of intermediate 7a: [ka]
[0101] Step 1: In a nitrogen gas atmosphere, magnesium scraps (14.59 g, 600 mmol), iodine grains (0.91 g, 3.6 mmol) and 50 mL of anhydrous THF were added in that order. The mixture was heated to 60°C, 1,2-dibromoethane (0.1 mL) was quickly added dropwise, and then 1,4-dibromobutane (14.3 mL, 120 mmol) was added dropwise. After the addition was completed, the mixture was reacted for 1 h with stirring. After the reaction was completed, the mixture was heated to 80°C, and intermediate 1a.3 (8.92 g dissolved in 20 mL of anhydrous THF, 30 mmol) was added, and the mixture was reacted for 2 h with stirring at the same temperature. After the reaction was completed, the mixture was quenched with ammonium chloride solution, filtered to obtain the filtrate, extracted with ethyl acetate, washed with sodium chloride solution, dried with anhydrous sodium sulfate, and concentrated by rotary evaporation under reduced pressure to obtain a mixture. Separation by silica gel column chromatography eluting with ethyl acetate:petroleum ether afforded intermediate 7a.3 (light yellow oil 4.36 g, 45%).
[0102] 1 H NMR (400 MHz, CDCl3) δ 7.34-7.29 (m, 8H), 7.28-7.22 (m, 2H), 6.70 (s, 1H), 3.93 (d, J = 12.8 Hz, 2H), 3.29-3.21 (m, 1H), 3.21 (d, J = 12.8 Hz, 2H), 2.18 (dd, J = 14.6, 11.8 Hz, 1H), 1.78-1.62 (m, 2H), 1.60-1.51 (m, 1H), 1.47-1.33 (m, 3H), 1.13 (dd, J = 14.6, 2.4 Hz, 1H), 1.08 (d, J = 6.7 Hz, 3H), 0.95-0.84 (m, 1H), 0.80-0.71 (m, 1H). 13 C NMR (100 MHz, CDCl3) δ 138.39, 129.76, 128.45, 127.33, 82.41, 52.88, 51.46, 42.37, 41.53, 38.08, 23.96, 23.47, 12.39.
[0103] Step 2: Referring to the procedure for synthesis of Bn removal in 1a, intermediate 7a was obtained as a white solid, which was directly used in the reaction of the next step. 1 H NMR (400 MHz, CDCl3) δ 3.21-3.08 (m, 1H), 1.88-1.40 (m, 10H), 1.13 (d, J = 6.4 Hz, 3H); 13 C NMR (100 MHz, CDCl3) δ 82.2, 47.4, 46.5, 41.7, 39.2, 28.2, 24.1, 23.7.
[0104] Preparation of compound 7: [ka]
[0105] Step 1: Compound 1b (346 mg, 0.84 mmol), compound 7a (300 mg, 2.1 mmol) and acetic acid (403 mg, 7.72 mmol) were added to 4 mL of acetonitrile and reacted for 6 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 7c, which was used as it was in the next step reaction. MS m / z(ESI): 488.2[M+1] + .
[0106] Step 2: Intermediate 7c was added to anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was reacted at 70-80°C for 6 h with stirring. After the reaction was completed, the mixture was quenched with 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 4 (light yellow solid, 70 mg, 17.6% yield for two steps). MS m / z (ESI): 474.2 [M+1] + .
[0107] 1H NMR (400 MHz, CDCl3) δ 12.47 (br s, 1H), 10.42 (t, J = 5.8 Hz, 1H), 8.34(s, 1H), 7.40-7.34 (m, 1H), 6.84-6.77 (m, 2H), 5.35 (t, J = 3.4 Hz, 1H), 4.83-4.75 (m, 1H), 4.66 (dd, J = 15.3, 6.0 Hz, 1H), 4.60 (dd, J = 15.3, 5.8 Hz, 1H), 4.30 (dd, J = 13.7, 3.4 Hz, 1H), 4.17(dd,J = 13.7, 3.5 Hz, 1H), 2.11 (dd, J = 14.5, 6.8 Hz, 1H), 2.07-1.89 (m, 2H), 1.83 (dd, J = 14.5, 8.1 Hz, 1H), 1.80-1.49 (m, 6H), 1.39 (d, J = 6.8 Hz, 3H).
[0108] Example 8 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (4'R, 12a'S)-N-(2, 4-difluorophenyl)-7'-hydroxy-4'-methyl-6', 8'-dioxo-3',4',6',8',12',12a'-hexahydrospiro[cyclohexane-1,2'-pyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazine]-9'-carboxamide.
[0109] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Preparation of intermediate 8a: [ka]
[0110] Step 1: Refer to the procedure conditions for intermediate 7a.3, using 1,5-dibromopentane to give intermediate 8a.3 (white solid, 2.68 g, 16%). 1 H NMR (400 MHz, CDCl3) δ 7.35-7.30 (m, 8H), 7.27-7.21 (m, 2H), 6.62 (s, 1H), 3.92 (d, J = 12.8 Hz, 2H), 3.24-3.13 (m, 1H), 3.19 (d, J = 12.8 Hz, 2H), 1.81 (dd, J = 14.8, 12.0 Hz, 1H), 1.70-1.58 (m, 1H), 1.52 (dd, J = 12.9, 5.6 Hz, 1H), 1.46-1.32 (m, 3H), 1.25-1.08 (m, 4H), 1.05 (d, J = 6.7 Hz, 3H), 0.71 (dd, J = 7.3, 4.8 Hz, 2H). 13 C NMR (100 MHz, CDCl3) δ 138.50, 129.90, 128.52, 127.40, 71.51, 52.95, 49.18, 42.67, 40.60, 35.77, 26.14, 22.24, 22.13, 12.52.
[0111] Step 2: Using the same procedure as for intermediate 1a for removing boron, intermediate 8a was produced as a white solid, which was used as it was in the next step. Synthesis of compound 8: [ka]
[0112] Step 1: Compound 1b (412 mg, 1 mmol), compound 8a (300 mg, 2.2 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and reacted for 16 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 7c, which was used as it was in the next step. MS m / z(ESI): 502.2[M+1] + .
[0113] Step 2: Intermediate 8c was added to anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was stirred at 70-80°C for 6 h. After the reaction was completed, the mixture was quenched by adding 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 8 (light yellow solid, 194 mg, 40.0% yield for two steps). MS m / z(ESI): 488.2[M+1] + .
[0114] 1 H NMR (400 MHz, CDCl3) δ 12.40 (br s, 1H), 10.48 (t, J = 5.9 Hz, 1H), 8.42 (s, 1H), 7.40-7.34 (m, 1H), 6.85-6.77 (m, 2H), 5.35 (t, J = 2.5 Hz, 1H), 4.70-4.59 (m, 3H), 4.28 (dd, J = 13.9, 3.1 Hz, 2H), 2.04 (dd, J = 15.0, 6.9 Hz, 1H), 1.80 (dd, J = 15.0, 10.4 Hz, 1H), 1.68-1.54 (m, 2H), 1.44-1.21 (m, 8H), 1.35 (d, J = 6.5 Hz, 3H).
[0115] Example 9 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (4R, 12aS)-N-(2, 4-difluorophenyl)-7'-hydroxy-4'-methyl-6', 8'-dioxo-2,3,3',4',5,6,6',8',12',12a'-decahydrospiro[pyran-4,2'-pyrido[1',2':4,5]pyrazino[2, 1-b][1,3]oxazine]-9'-carboxamide.
[0116] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Preparation of intermediate 9a: [ka]
[0117] Process: The preparation method is based on the reference Tetrahedron Asymmetry 1996, 2911-2922. (R)-2-aminopropanol is used as the raw material, and after Bz amino protection and hydroxychlorination, it is added to tetrahydropyrone in the n-BuLi / lithium naphthalenide system, and finally Bz is deprotected to obtain intermediate 9a. MS m / z(ESI): 160.23[M+1] + .
[0118] 1 H NMR(DMSO-d6)δ 3.64-3.48 (m, 4H), 3.53-3.36 (m, 3H), 3.12-2.85 (m, 1H), 1.51-1.26 (m, 6H), 1.02 (d, J = 6.4 Hz, 3H);
[0119] Synthesis of compound 9: [ka]
[0120] Step 1: Compound 1b (412 mg, 1 mmol), compound 9a (318 mg, 2 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and reacted for 10-12 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 9c, which was used as it was in the next step reaction. MS m / z (ESI): 504.2 [M+1] + .
[0121] Step 2: Intermediate 9c was added to anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was reacted at 70-80° C. for 6-8 h with stirring. After the reaction was completed, the mixture was quenched with 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 9 (light yellow solid, 68 mg, 13.9% yield for two steps). MS m / z(ESI): 490.2[M+1] + .
[0122] 1H NMR (400 MHz, CDCl3) δ 12.31 (br s, 1H), 10.40 (t, J = 5.8 Hz, 1H), 8.36 (s, 1H), 7.40-7.34 (m, 1H), 6.85-6.77 (m, 2H), 5.39 (t, J = 2.1 Hz, 1H), 4.74-4.60 (m, 3H), 4.31 (dd, J = 13.9, 3.0 Hz, 1H), 4.24 (dd, J = 14.0, 1.9 Hz, 1H), 3.72-3.65 (m, 2H), 3.60 (dt, J = 11.6, 4.2 Hz, 1H), 3.48 (td, J = 11.1, 2.6 Hz, 1H), 2.04 (dd, J = 15.0, 6.9 Hz, 1H), 1.90 (dd, J = 15.0, 10.3 Hz, 1H), 1.74-1.62 (m, 2H), 1.59 (dd, J = 10.8, 4.7 Hz, 1H), 1.55(dd, J = 10.8, 4.6 Hz, 1H), 1.39 (d, J = 6.5 Hz, 3H).
[0123] Example 10 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (3R,11aS)-N-(2,4-difluorophenyl)-6-hydroxy-3-methyl-5,7-dioxo-5,7,11,11a-tetrahydro-3H-spiro[cyclopropane-1,2-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8-carboxamide.
[0124] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Preparation of intermediate 10a: [ka]
[0125] Step 1: In a nitrogen gas atmosphere, compound 1a.1 (4.06 g, 20 mmol) was placed in 40 mL of anhydrous THF and cooled to -30 to -35°C. Ti(O i Pr)4 (0.3 equivalents), EtMgBrs (2M / Et2O, 3.0 equivalents) were added dropwise and reacted with stirring for 1 h, then transferred to -5 to 0 °C and reacted with stirring for 10-12 h. After the reaction was completed, the mixture was quenched with ammonium chloride solution, extracted with ethyl acetate, washed with sodium chloride solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The mixture was separated by silica gel column chromatography and eluted with gradient ethyl acetate and petroleum ether to obtain intermediate 10a.2 (white solid 0.6 g, 15%).
[0126] 1 H NMR (400 MHz, CDCl3) δ 3.31 (q, J = 6.8 Hz, 1H), 1.45 (s, 9H), 1.23 (d, J = 6.9 Hz, 3H), 0.82-0.72 (m, 3H), 0.54-0.51 (s, 1H).
[0127] Step 2: Intermediate 10a.2 (390 mg, 1.94 mmol) was added to 4 mL dioxane, and 3M hydrochloric acid solution in dioxane (7.76 mmol) (preparation of 3M hydrochloric acid: 1 mL concentrated hydrochloric acid was added to 3 mL dioxane) was added dropwise and reacted at room temperature for 20-22 h with stirring. After completion of the reaction, the reaction solution was concentrated under reduced pressure and dehydrated several times with acetonitrile to obtain a pink oily substance. 4 mL acetonitrile was added and refrigerated for 10-12 h, filtered, washed with cold acetonitrile, and dried to obtain intermediate 10a (white solid 180 mg, 91.8%).
[0128] 1 H NMR (400 MHz, DMSO-d6) δ 8.15 (br s, 3H), 5.81 (br s, 1H), 2.79-2.74 (m ,1H), 1.23 (d, J = 6.7 Hz, 3H), 0.72-0.54 (m, 4H).
[0129] Synthesis of compound 10: [ka]
[0130] Step 1: Compound 1b (206 mg, 0.5 mmol) was added to 3 mL of acetonitrile solution, and DIEA (130 mg, 1 mmol) was added to a separate acetonitrile (2 mL) solution of compound 10a hydrochloride (138 mg, 1 mmol) and mixed uniformly. The mixture was then added to the acetonitrile solution of compound 1b, and finally acetic acid (150 mg, 2.5 mmol) was added, and the mixture was stirred at 70-80°C for 4-5 h. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 10c, which was used as it was in the next step reaction. MS m / z(ESI): 446.2[M+1] + .
[0131] Step 2: Intermediate 10c was added to anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was stirred at 70-80°C for 6-8 h. After the reaction was completed, the mixture was quenched with 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated to obtain a mixture. The mixture was separated by silica gel column chromatography, eluted with dichloromethane / methanol gradient, and purified to obtain compound 10 (off-white solid, 142 mg, 66% yield for two steps). MS m / z(ESI): 432.2[M+1] + .
[0132] 1H NMR (400 MHz, CDCl3) δ 11.47 (br s, 1H), 10.31 (s, 1H), 8.36 (s, 1H), 7.38-7.32 (m, 1H), 6.83-6.78 (m, 2H), 5.41-5.39 (m, 1H), 4.68-4.56 (m, 1H), 4.45 (dd, J = 12.3, 3.0 Hz, 1H), 4.35 (q, J = 6.1 Hz, 1H), 3.98 (t, J = 11.2 Hz, 1H), 1.34 (d, J = 6.2 Hz, 3H), 1.25-1.10 (m, 1H), 0.94-0.76 (m, 3H).
[0133] Example 11 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (3'R,11a'S)-N-(2,4-difluorophenyl)-6'-hydroxy-3'-methyl-5',7'-dioxo-5',7',11',11a'-tetrahydro-3'H-spiro[cyclopentane-1,2'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide.
[0134] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Preparation of intermediate 11a: [ka]
[0135] Step 1: Referring to the operating conditions of 7a.3, intermediate 11a.1 was charged into the freshly prepared Grignard reaction mixture 7a.2 to produce intermediate 11a.2 (light yellow oil, 3.91 g, 50%).
[0136] 1H NMR (400 MHz, CDCl3) δ 7.35-7.27 (m, 8H), 7.26-7.21 (m, 2H), 4.35 (s, 1H), 3.89 (d, J = 13.5 Hz, 2H), 3.34 (d, J = 13.5 Hz, 2H), 2.92 (q, J = 7.0 Hz, 1H), 1.90-1.78 (m, 1H), 1.78-1.68 (m, 1H), 1.69-1.54 (m, 3H), 1.52-1.38 (m, 3H), 1.09 (d, J = 7.0 Hz, 3H). 13 C NMR (100 MHz, CDCl3) δ 139.53, 129.09, 128.55, 127.30, 82.63, 59.33, 55.09, 38.98, 35.53, 24.89, 23.12, 7.13.
[0137] Step 2: Following the conditions for Bn removal in 1a, oily product 11a was produced, which was used as it was in the next step. Synthesis of compound 11: [ka]
[0138] Step 1: Compound 1b (251 mg, 0.84 mmol), compound 7a (160 mg, 1.22 mmol) and acetic acid (220 mg, 3.66 mmol) were added to 3 mL of acetonitrile and reacted for 16 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 11c, which was used as it was in the next step reaction. MS m / z(ESI): 474.2[M+1] + .
[0139] Step 2: Intermediate 11c was placed in anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was reacted at 70-80°C for 6-8 h with stirring. After the reaction was completed, 0.5M sulfuric acid solution was added to quench the reaction, 3-5 mL of water was added and stirred to precipitate a solid, which was then filtered, washed with THF / water = 1:1, and dried to obtain compound 11 (white solid, 230 mg, 63.5% yield for 2 steps). MS m / z (ESI): 432.2 [M+1] + .
[0140] 1 H NMR (400 MHz, DMSO-d6) δ 11.44 (br s, 1H), 10.33 (t, J = 3.6Hz, 1H), 8.46 (s, 1H), 7.43-7.37 (m, 1H), 7.28-7.22 (m, 1H), 7.09-7.04 (m, 1H), 5.42 (d, J = 10.2, 4.0 Hz, 1H), 4.83 (d, J = 12.2, 4.0 Hz, 1H), 4.59-4.50 (m, 2H), 4.17 (q, J = 6.5 Hz, 1H), 3.99 (dd, J = 11.6, 10.44 Hz, 1H), 1.79-1.59 (m, 8H), 1.30 (d, J = 6.7 Hz, 3H).
[0141] Example 12 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] and named it (3'R,11a'S)-N-(2,4-difluorophenyl)-6'-hydroxy-3'-methyl-5',7'-dioxo-5',7',11',11a'-tetrahydro-3'H-spiro[cyclohexane-1,2'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide.
[0142] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Preparation of intermediate 12a: [ka]
[0143] Step 1: Referring to the operating conditions of 7a.3, intermediate 11a.1 was used in a Grignard reaction to prepare intermediate 12a.1 (white solid, 2.03 g, 12%). 1 H NMR (400 MHz, CDCl3) δ 7.34-7.29 (m, 7H), 7.28-7.21 (m, 1H), 3.89 (d, J = 13.7 Hz, 2H), 3.71 (s, 1H), 3.36 (d, J = 13.7 Hz, 2H), 2.61 (q, J = 7.1 Hz, 1H), 1.73-1.18 (m, 10H), 1.09 (d, J = 7.1 Hz, 3H). 13 C NMR (100 MHz, CDCl3) δ 139.62, 129.10, 128.53, 127.28, 72.56, 62.38, 56.18, 36.32, 33.35, 26.05, 22.42, 21.96, 7.50.
[0144] Step 2: Following the conditions for Bn removal in 1a, oily product 12a was prepared, which was used as it was in the next step. Synthesis of compound 12: [ka]
[0145] Step 1: Compound 1b (231 mg, 0.56 mmol), compound 12a (200 mg, 1.4 mmol) and acetic acid (202 mg, 3.36 mmol) were added to 3 mL of acetonitrile and reacted for 4-5 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to obtain intermediate 11a, which was used as it was in the next step reaction. MS m / z(ESI): 488.2[M+1]+ .
[0146] Step 2: Intermediate 11c was added to anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was stirred at 70-80°C for 10-12 h. After the reaction was completed, the mixture was quenched by adding 0.5M sulfuric acid solution, extracted with ethyl acetate, washed with sodium bicarbonate solution, dried with anhydrous sodium sulfate, filtered and concentrated to obtain a mixture, which was crystallized with methyl-t-butyl ether for 2-4 h, filtered, washed with methyl-t-butyl ether and dried to obtain compound 12 (off-white solid, 180 mg, 67.9% yield for two steps). MS m / z(ESI): 474.2[M+1] + .
[0147] 1 H NMR (400 MHz, CDCl3) δ 11.55 (br s, 1H), 10.33 (t, J = 5.7 Hz, 1H), 8.35 (s, 1H), 7.39-7.32 (m, 1H), 6.84-6.77 (m, 2H), 5.40 (dd, J = 10.1, 4.0 Hz, 1H), 4.65 (dd, J = 16.0, 6.2 Hz, 1H), 4.61 (dd, J = 16.2, 6.2 Hz, 1H), 4.42 (dd, J = 12.4, 4.2 Hz, 1H), 4.13 (q, J = 6.7 Hz, 1H), 3.87 (dd, J = 12.3, 10.3 Hz, 1H), 1.80-1.50 (m, 10H), 1.36 (d, J = 6.8 Hz, 3H).
[0148] Example 13 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] in, (2,4-difluorophenyl)-7'-hydroxy-6',8'-dioxo-2',3',6',8',12',12a'-hexahydrospiro[cyclopropane-1,4'-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine]-9'-carboxamide (compound 13), (S)-N-(2,4-difluorophenyl)-7'-hydroxy-6',8'-dioxo-2',3',6',8',12',12a'-hexahydrospiro[cyclopropane-1,4'-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine]-9'-carboxamide (compound 14), The compound was named (R)-N-(2,4-difluorophenyl)-7'-hydroxy-6',8'-dioxo-2',3',6',8',12',12a'-hexaspiro[cyclopropane-1,4'-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine]-9'-carboxamide (compound 15).
[0149] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Preparation of intermediate 13a: [ka]
[0150] Steps 1 and 2: Referring to the synthetic route in the literature Journal of Medicinal Chemistry, 2016, 59, 8, 3732-3749, 2-cyanoethanol was used as a raw material, and the hydroxyl group was protected by TBSCl, and then the Klinkovich reaction of cyclopropane was carried out to produce an amino alcohol protected by TBS.
[0151] 1H NMR (DMSO-d6) δ 3.78 (t, J = 6.8 Hz, 1H), 1.65 (br s, 2H), 1.53 (t, J = 6.9 Hz, 2H), 0.83 (s, 9H), 0.37-0.30 (m, 3H), 0.04(s, 6H).
[0152] Step 3: Deprotection of TBS with acetic acid afforded reddish brown oil 13a, which was used as such in the next step reaction. Synthesis of compounds 13, 14 and 15: [ka]
[0153] Step 1: Compound 1b (412 mg, 1 mmol), compound 13a (202 mg, 2 mmol) and acetic acid (360 mg, 6 mmol) were added to 4 mL of acetonitrile and reacted for 14-16 h with stirring at 70-80°C. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain intermediate 13c, which was used as it was in the next step reaction. MS m / z(ESI): 446.1[M+1] + .
[0154] Step 2: Intermediate 13c was placed in anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was stirred at 70-80°C for 4-6 h. After the reaction was completed, 0.5M sulfuric acid solution was added to quench the reaction, water was added and stirred for 1-3 h to precipitate crystals, and the mixture was filtered and washed with THF:water = 1:1 to obtain compound 13 (off-white solid, 177 mg, 41% yield for 2 steps). MS m / z (ESI): 432.2 [M+1] + .
[0155] 1H NMR (400 MHz, DMSO-d6) δ 12.53 (br s, 1H), 10.41 (t, J = 5.8 Hz, 1H), 8.57 (s, 1H), 7.48-7.42 (m, 1H), 7.33-7.27 (m, 1H), 7.15-7.10 (m, 1H), 5.38-5.34 (d, 1H), 4.74 (dd, J = 14.7, 1.2 Hz, 1H), 4.63 (dd, J = 15.2, 6.2 Hz, 1H), 4.57 (dd, J = 15.0, 5.7 Hz, 1H), 4.43 (dd, J = 14.4, 2.9 Hz, 1H), 4.15 (dd, J = 11.1, 4.8 Hz, 1H), 4.07 (td, J = 11.8, 2.3 Hz, 1H), 2.33 (td, J = 12.4, 5.2, 1H), 1.52-1.47 (m, 1H), 1.18-1.08 (m, 2H), 0.88-0.82 (m, 1H), 0.77-0.72 (m, 1H).
[0156] Preparation of chiral compounds 14 and 15: Compound 14 (retention time: 1.21 min, MS m / z (ESI): 432.1 [M+1]) was isolated from the suspension 13 (50 mg) by SFC separation (preparative column: ChiralPak AD, 250 × 30 mm ID, 10 μm; mobile phase: CO2 in phase A / isopropanol in phase B, gradient: B 25%, flow rate: 70 ml / min, column pressure: 100 bar, column temperature: 38 °C, wavelength: 220 nm). + ), compound 15 (retention time: 1.46 min, m / z (ESI): 432.1 [M+1] + ) was manufactured.
[0157] Chiral HPLC purification method (preparative column: ChiralPak AD, 150×4.6 mm ID, 3 μm; mobile phase: A phase CO2 / B phase isopropanol (0.05% DEA), gradient: B 40%, flow rate: 2.5 ml / min, column pressure: 100 bar, column temperature 35° C., wavelength 220 nm).
[0158] Example 14 An embodiment of the present invention provides a polycyclic carbamoylpyridone derivative, the structural formula of which is: [ka] in, N-(2,4-difluorophenyl)-6'-hydroxy-5',7'-dioxo-5',7',11',11a'-tetrahydro-2'H-spiro[cyclopropane-1,3'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide (compound 16), (S)-N-(2,4-difluorophenyl)-6'-hydroxy-5',7'-dioxo'-5',7',11',11a'-tetrahydro-2'H-spiro[cyclopropane-1,3'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide (compound 17), The compound was named (R)-N-(2,4-difluorophenyl)-6'-hydroxy-5',7'-dioxo'-5',7',11',11a'-tetrahydro-2'H-spiro[cyclopropane-1,3'-oxazolo[3,2-a]pyrido[1,2-d]pyrazine]-8'-carboxamide (compound 18).
[0159] An embodiment of the present invention provides a method for preparing the polycyclic carbamoylpyridone derivatives, comprising the steps of: Synthesis of compounds 16, 17 and 18: [ka]
[0160] Step 1: Compound 1b (618 mg, 1.5 mmol) was added to 5 mL of acetonitrile solution, and DIEA (387 mg, 3 mmol) was added to a separate acetonitrile (1 mL) solution of compound 16a hydrochloride (371 mg, 3 mmol) and mixed uniformly. The mixture was then added to the acetonitrile solution of compound 1b, and finally acetic acid (540 mg, 9 mmol) was added. The mixture was stirred at 70-80°C for 20-24 h. After the reaction was completed, the mixture was washed with aqueous sodium bicarbonate, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain intermediate 16c, which was used as it was in the next step. MS m / z(ESI): 432.2[M+1] + .
[0161] Step 2: Intermediate 16c was placed in anhydrous THF, LiBr (4.0 equivalents) was added, and the mixture was stirred at 70-80°C for 6-8 h. After the reaction was completed, 0.5M sulfuric acid solution was added to quench the reaction, and the mixture was stirred for 2-4 h to precipitate a solid. The solid was filtered, washed with THF / water = 1:1, and dried to obtain compound 10 (off-white solid, 230 mg, 36.7% yield for 2 steps). MS m / z (ESI): 418.2 [M+1] + .
[0162] 1 H NMR (400 MHz, CDCl3) δ 11.70 (br s, 1H), 10.25 (s, 1H), 8.27 (s, 1H), 7.31-7.25 (m, 1H), 6.77-6.71 (m, 2H), 5.32 (dd, J = 10.1, 3.6 Hz, 1H), 4.56 (d, J = 5.8 Hz, 2H), 4.41 (dd, J = 12.2, 3.5 Hz, 1H), 4.13 (d, J = 8.6 Hz, 1H), 4.06-3.95 (m, 2H), 2.19-2.11 (m,1H), 2.02-1.94 (m, 1H), 0.83-0.73 (m, 2H).
[0163] Preparation of chiral compounds 17 and 18: Suspension 16 (100 mg) was separated by SFC (preparative column: ChiralPak AD, 250×30 mm ID, 10 μm; mobile phase: CO2 A / isopropanol B (0.1% aqueous ammonia), gradient: B40%, flow rate: 80 ml / min, column pressure: 100 bar, column temperature 38° C., wavelength 220 nm).
[0164] Compound 17 (51 mg, retention time 2.79 min, MS m / z (ESI): 418.1 [M+1] + ), compound 18 (39 mg, retention time 5.84 min, MS m / z (ESI): 418.1 [M+1] + ) was manufactured. Chiral HPLC purification method (preparative column: ChiralPak AD, 150×4.6 mm ID, 3 μm; mobile phase: A phase CO2 / B phase isopropanol (0.05% DEA), gradient: B 40%, flow rate: 2.5 ml / min, column pressure: 100 bar, column temperature 35° C., wavelength 220 nm).
[0165] Example 15: Evaluation of Compounds The properties of the compound of the present invention were verified by a compound activity test, an integrase inhibitory activity test, a compound oil-water partition coefficient, a compound PK test (mouse), and a compound PK test (cynomolgus monkey).
[0166] The structures of the control drugs in the above tests are as follows: [ka]
[0167] 1. Activity test 1. Experimental Materials -Virus: The HIV-1 pseudotype virus used in this study was a replication-defective virus constructed by Yasunori Yakami. - The cell line HEK 293T cells were purchased from ATCC, catalog number CRL-11268. The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% double antibiotics.
[0168] -reagent [Table 1]
[0169] -Main equipment [Table 2]
[0170] 2. Experimental Method [Table 3]
[0171] (1) Inoculating cells into plates: On the first day, HEK 293T cells were seeded into a 96-well test plate at a density of 55,000 cells / well, 100 μL per well, and cultured overnight in a 5% CO2, 37°C incubator.
[0172] (2) Compound treatment and virus infection: On the second day, the test compounds (compounds provided by the examples of the present invention) and control compounds were diluted 4-fold in cell culture medium to give a total of eight concentrations, with 50 μL of diluted compound added to each well in duplicate. Then, HIV-1 pseudotyped virus was diluted to 100 TCID50 / 50 μL in cell culture medium, and 50 μL of diluted virus was placed in each well.
[0173] Cell controls (cells without compound treatment or virus infection) and virus controls (cells infected with virus but without compound treatment) were set up. The final initial test concentration of test compounds and control compounds was 1000 nM (Table 1), and the virus infection dose was 100 TCID50 / well. The total volume of cell culture medium was 200 μL / well, and the final concentration of DMSO in the culture medium was 0.5%. The cells were then cultured in a 5% CO2, 37°C incubator for three days.
[0174] (3) Detection of luciferase activity: On the fifth day, 100 μL of cell supernatant was aspirated from each well of the antiviral activity detection plate, and 100 μL of 2× luciferase reporter gene detection reagent Britelite plus was added to the wells in the test plate in the dark. The luciferase activity of each well in the test plate was detected by Envision. The data was used for the antiviral activity analysis of the samples.
[0175] (4) Detection of cytotoxicity: On the fifth day, 100 μL of cell supernatant was aspirated from each well of the cytotoxicity detection plate, and 100 μL of cell vitality detection reagent CellTiter Glo was added in the dark. The cell vitality of each well was detected by a BioTek microplate reader, and the data was used for the cytotoxicity analysis of the samples.
[0176] (5) Data processing: The dose-effect curves were plotted using GraphPad Prism software. The formulas for calculating the antiviral activity (%Inhibition) and cell viability (%cell viability) were as follows: Antiviral activity (%) = (test well reading - mean value of virus control) / (mean value of cell control - mean value of virus control) x 100 Cell vitality (%) = (test well reading - mean of medium control) / (mean of cell control - mean of medium control) x 100
[0177] EC 50 and C.C. 50 The values were calculated by performing a nonlinear fitting analysis of the inhibitory activity of the compound and the cell viability using GraphPad Prism (version 5) software, and the fitting method was "log(inhibitor) vs. response -- Variable slope".
[0178] 3. Using HIV-1 pseudotype virus experiments, the effects of the test compounds on in vitro antiviral activity and cytotoxicity in HEK 293T cells were measured, and the experimental results are shown in the table below. [Table 4]
[0179] The results showed that the control compounds RAL, DTG and the test compounds all had antiviral activity against HIV-1 pseudotyped viruses, and the compounds did not show obvious cytotoxicity in HEK 293T cells. 50 values were shown to be greater than the highest tested concentration.
[0180] II. Integrase activity test In this experiment, we quantitatively measured the integrase activity using a non-radioactive assay kit. HIV-1 integrase cleaves two bases at the 3'-end of donor double-stranded DNA (DS DNA), and incorporates the cleaved DS DNA into double-stranded target substrate DNA (TS DNA) containing a 3'-end modification, which is specifically modified at the 3'-end by an HRP-labeled antibody. The absorbance value was read at 450 nm, and the integrase activity was quantified.
[0181] 1. Reagents and Materials: HIV-1 Integrase Assay Kit # EZ-1700 14.5 M β-mercaptoethanol (BME), metal bath, thermostatic oven, 96-well culture plate (NEST) benchtop microplate reader (SpectraMaxR iD5), DMSO; Test compounds: Compound 1, Dolutegravir (DTG), Bictegravir (BIC)
[0182] 2. Test Procedure (1) Preparation of reagents: Each component was prepared according to the kit instructions. The test product was prepared by preparing a 5 mM DMSO solution of the test product for use, preparing a working solution at the initial final concentration determined during method establishment, and diluting it in a 4-fold gradient to a concentration of 10. (2) Establishment of methodology: Methodology was established using the EZ-1700 kit. <1> Data reproducibility experiments were performed by Azide to determine antibody incubation times. <2> The detection concentrations of compound 1, DTG, and BIC were explored.
[0183] (3) Test item testing <1> Working solutions of the test articles were prepared at initial concentrations determined during methodology establishment. <2> Reagent preparation was performed according to the method provided in the kit. <3> Coat DS DNA – Block – Add integrase solution – Add test article – Add TS DNA – Add HRP antibody – Add TMB peroxidase substrate – Stop reaction with TMB – Detect absorbance at 450 nm. The IC was calculated using the formula Log(inhibitor) vs. response - variable slope using the software Graphpad Prism 8.0. 50 Curve fitting was performed.
[0184] The IC of the compounds of the present invention measured in the above test 50 The values are shown in the table below. [Table 5] Conclusion: The compounds of the present invention can inhibit HIV integrase activity, and have better inhibitory effect on integrase activity than dolutegravir (DTG) and bictegravir (BIC).
[0185] 3. Oil-water partition coefficient of the compound Oil-water partition coefficient of a compound a) Each 5 mL glass bottle was charged with 1 mL of n-octanol and 1 mL of pH 7.4 phosphate buffer. b) Compound stock solutions were prepared at a concentration of 10 mM in DMSO, and 20 μL of compound stock solution was added to a mixture of n-octanol and phosphate buffer.
[0186] c) The sample was shaken uniformly at room temperature for 1 hour at a shaking speed of 300 / min. d) After leaving the solution to stand for 30 minutes, the solution was completely separated into layers. The upper and lower layers were then sucked into a 96-well deep well plate and loaded into an LC-MS / MS for detection. e) Aliquots of the 1-octanol and aqueous phase solutions were serially diluted with DMSO to obtain the final samples used for LC-MS / MS analysis. Three serial dilutions were performed for each 1-octanol phase, covering a 2500-fold concentration range. Two serial dilutions were performed for each final aqueous phase, covering a 100-fold concentration range. The MS peak areas of these solutions were used to generate a log(peak area) by log(relative concentration) calibration curve.
[0187] LogD(pH7.4)=LOG(Coct / Caq) Coct = sample concentration in n-octanol Caq = sample concentration in pH 7.4 phosphate buffer [Table 6]
[0188] Conclusion: At pH 7.4, the log D values of DTG, compound 6, compound 1, and compound 2 were 1.6, 2.0, 2.2, and 2.5, respectively, suggesting that all of these compounds have good small intestinal absorption. In addition, in the process of small intestinal absorption, the higher the log D value, the better the lipid solubility and cell permeability. Therefore, the order of cell permeability of the above compounds is compound 2>compound 1>compound 6>DTG.
[0189] 4. Compound PK test (mouse) 1. Summary ICR mice were used as test animals, and the plasma drug concentrations at different time points after mice were administered compounds (compound 1, compound 2, compound 6, compound 10) and positive control (DTG) by intragastric administration (PO) and intravenous injection (IV) were measured by LC-MSMS. The pharmacokinetic behavior of this compound in mice was studied, and its pharmacokinetic characteristics were evaluated.
[0190] 2. Test Drugs Compound 1, Compound 2, Compound 6, Compound 10 and the positive control dolutegravir (DTG). 3. Test Animals The mice were SPF ICR males, 10 weeks old, weighing approximately 32 g, with 6 mice in each group, for a total of 48 mice.
[0191] 4. Test Formulation Intragastric administration group (PO): 5% DMSO / 10% Solutol / 85% (20% Captisol aqueous solution); Intravenous group (IV): 5% DMSO / 10% Solutol / 85% (20% Captisol aqueous solution).
[0192] 5. Administration Mice were deprived of food at 5:00 pm on the day before administration, fasted overnight, and allowed to consume water. Mice were administered 2 mg / kg IV and 10 mg / kg PO. Food intake was resumed 2 hours after administration.
[0193] 6. Sampling For intragastric administration of mice, 20 μL of blood was collected from the saphenous vein of the tibia before administration and 0.25, 0.5, 1, 2, 4, 8, and 24 hours after administration, respectively, and placed in an EDTA-K2 anticoagulant blood collection tube. The blood sample was placed on ice until centrifuged to obtain a plasma sample. The plasma sample was centrifuged at 4°C (3500 rpm, 10 min), and after separation, the sample was transferred to an EP tube and stored at -80°C until detection.
[0194] For intravenous administration in mice, 20 μL of blood was collected from the saphenous vein of the tibia at 0.0833, 0.25, 0.5, 1, 2, 4, 8, and 24 hours before and after administration, respectively, and placed in an EDTA-K2 anticoagulant blood collection tube. The blood sample was placed on ice until centrifuged to obtain plasma samples. The plasma samples were centrifuged at 4°C (3500 rpm, 10 min), and after separation, the samples were transferred to EP tubes and stored at -80°C until detection.
[0195] 7. Detection The content of the test compound in the plasma of mice after intragastric administration of different concentrations of drugs was measured. 10 μL of mouse plasma was taken at each time point after administration, and 100 μL of methanol (100 ng / mL) containing the internal standard was added, mixed by vortex for 1 min, and centrifuged at 4°C (12000 rmp, 5 min). 1 μL of the supernatant was taken from the plasma sample and analyzed by LC-MS / MS.
[0196] 8. Pharmacokinetic parameters results [Table 7]
[0197] 9. Summary The mouse PK test results showed that compounds 1, 2, 6, and 10 had good bioavailability, with compound 1 showing better bioavailability and half-life data than the positive control DTG.
[0198] 5. Compound PK study (cynomolgus monkeys) 1. Summary Cynomolgus monkeys were used as test animals, and the plasma drug concentrations at different time points after the cynomolgus monkeys were administered Compound 1 by intragastric administration (PO) were measured by LC-MS / MS. The pharmacokinetic behavior of the disclosed compound in the cynomolgus monkey was studied, and its pharmacokinetic characteristics were evaluated.
[0199] 2. Test Drugs Compound 1. 3. Test Animals Cynomolgus monkeys (Macaca fascicularis), normal size, male, approximately 2.5-4 years old, with a weight range of 2-5 kg, 3 per group.
[0200] 4. Test Formulation Compound 1 and a solid substrate (hydroxypropyl methylcellulose acetate succinate) were dissolved in an organic solvent, and the solvent was removed by evaporation through heating, or the solution was removed using a spray drying apparatus, to obtain compound 1 attached to the solid substrate.
[0201] Compound 1 attached to the solid substrate obtained in the above process was slowly added to a suitable container containing about 80% of the final volume of the solvent while stirring. Stirred until visually homogeneous, and sonicated the formulation if necessary. Solvent was added to the required concentration. The resulting formulation was continued to be stirred until the formulation was visually homogeneous, and sonicated the formulation if necessary. The API concentration was prepared to a dosage concentration of 20 mg / mL, and the above solvent was prepared by adding purified water of about 30% of the total volume to a suitable container and heating it to about 80°C-90°C, slowly adding the required volume of Tween 80 to the above container and stirring at the same time until homogeneous. Purified water was added to the final volume. Stirred until the solution was visually homogeneous.
[0202] 5. Administration Macaques were fasted overnight and allowed to drink water ad libitum. The PO group was administered 100 mg / kg. Food intake was allowed to resume 2 hours after administration.
[0203] 6. Sampling For intragastric administration in cynomolgus monkeys, 20 μL of blood was collected from the hind leg vein before administration and 0.25, 0.5, 1, 0.25, 0.5, 1, 2, 4, 8, 24, 48, 72, and 96 hours after administration, placed in EDTA-K2 anticoagulant blood collection tubes, and kept on ice until centrifuged to obtain plasma samples. Plasma samples were centrifuged at 4°C (3500 rpm, 10 min), and after separation, samples were transferred to EP tubes and stored at -80°C until detection.
[0204] 7. Detection The content of the test compound in the plasma of cynomolgus monkeys after intragastric administration of different concentrations of drugs was measured. After administration, 10 μL of cynomolgus monkey plasma was taken at each time point, and 100 μL of methanol (100 ng / mL) containing the internal standard was added, mixed by vortex for 1 min, centrifuged at 4°C (12000 rmp, 5 min), and 1 μL of the supernatant was taken from the plasma sample and analyzed by LC-MS / MS.
[0205] 8. Pharmacokinetic parameters results [Table 8]
[0206] 9. Summary The results of this test showed that the T 1 / 2 It was shown that the half-life was 15.7±5.49 h and 19.8±4.78 h. The preferred compound 1 of the present invention has a long half-life, which can reduce the administration frequency of AIDS patients, overcome the inconvenience of multiple administrations, and better meet the medical administration requirements.
[0207] The above description is only a preferred embodiment of the present invention, and does not limit the present invention. Those skilled in the art can make various modifications and changes to the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention are included in the protection scope of the present invention.
Claims
1. A polycyclic carbamoylpyridone derivative including a compound represented by formula (I)-1 or (I)-2, an isomer thereof, a pharma- ceutically acceptable salt, a hydrate or a solvate thereof, 【Chemistry 1】 Here, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 each independently represents a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, -OR 7 a substituted or unsubstituted aryl group, a substituted or unsubstituted monocyclic heteroaryl ring, a substituted or unsubstituted monocyclic heterocycle, and a cyano group; And the following (1)-(3): (1) R 1 and R 2 , (2) R 3 and R 4 , (3) R 5 and R 6 At least one pair of functional groups among the above forms a spiro ring or spiro hetero ring together with the carbon atom connected to the A ring, R 7 is selected from any one of hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, and a substituted or unsubstituted alkynyl group; m is any natural number between 0 and 5 The polycyclic carbamoylpyridone derivative,
2. R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each independently hydrogen, halogen, a C1-4 alkyl group, a C1-C4 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, -OR 7 , a C3-C8 cycloalkyl group, a C6-C10 aryl group, a 5-6 membered monocyclic heteroaryl ring, a 4-6 membered saturated monocyclic heterocycle, and a cyano group; And the following (1)-(3): (1) R 1 and R 2 , (2) R 3 and R 4 , (3) R 5 and R 6 At least one pair of functional groups among the above forms a 3- to 8-membered spiro ring or a 3- to 8-membered spiro hetero ring together with the carbon atom linked to the A ring, R 7 is selected from any one of hydrogen, a C1-4 alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, and a C1-C4 haloalkyl group; m is 0, 1, 2 or 3 The polycyclic carbamoylpyridone derivative according to claim 1 .
3. In the compounds represented by formula (I)-1 and formula (I)-2, the tertiary carbon atom linked to the A ring and the fused pyrazine has chirality; The compounds represented by formula (I)-1 and formula (I)-2 include compounds of a single configuration or a mixture of isomers, The isomers include at least one of tautomers, cis-trans isomers, racemates, and optical isomers having a mirror image or non-mirror image relationship. The polycyclic carbamoylpyridone derivative according to claim 1 or 2,
4. The polycyclic carbamoylpyridone derivative has the following structural formula: 【Chemistry 2】 2. The polycyclic carbamoylpyridone derivative according to claim 1, which is selected from any one of the compounds represented by the following formula:
5. The polycyclic carbamoylpyridone derivative has the following structural formula: 【Chemistry 3】 The polycyclic carbamoylpyridone derivative according to claim 1, which is a compound represented by the formula:
6. A method for producing the polycyclic carbamoylpyridone derivative according to any one of claims 1 to 5, comprising the steps of: 【Chemistry 4】 The method of the present invention is characterized in that the polycyclic carbamoylpyridone derivative is synthesized by referring to the following formula:
7. The conditions for preparing intermediate IV-1 include: the molar ratio of compound II to compound III-1 is 1:1-1:5; the temperature is 30-100° C.; and the time is 5 minutes-16 hours. The conditions for preparing intermediate IV-2 include: the molar ratio of compound II to compound III-2 is 1:1-1:5; the temperature is 30-100° C.; and the time is 5 minutes-16 hours. The conditions for preparing the compound represented by general formula (I)-1 include a temperature of 30-100°C and a time of 5 minutes to 16 hours. The conditions for preparing the compound represented by general formula (I)-2 include a temperature of 30-100° C. and a time of 5 minutes to 16 hours. The method according to claim 6 .
8. A pharmaceutical composition comprising the polycyclic carbamoylpyridone derivative according to any one of claims 1 to 5, its isomer, pharma- ceutically acceptable salt, hydrate or solvate, and a pharma- ceutically acceptable carrier.
9. The pharmaceutical composition according to claim 8, wherein the pharma- ceutical acceptable carrier is selected from water for injection, lyophilized powder adjuvant or oral administration formulation adjuvant.
10. Use of a polycyclic carbamoylpyridone derivative according to any one of claims 1 to 5 or a pharmaceutical composition according to claim 8 or 9 in the manufacture of a drug for preventing and / or treating a disease mediated by AIDS virus infection.
Citation Information
Patent Citations
Polycyclic pyridone compound with antiviral effect as well as pharmaceutical composition and application thereof
CN112521386A
Polycyclic carbamoylpyridone derivatives with HIV integrase inhibitory activity
JP2008540343A
Polycyclic pyridone derivative having integrase-inhibiting activity
WO2016027879A1
